newsfilter
← Latest News
PR Newswire·

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing